 CAMBRIDGE, Mass.--BUSINESS WIRE--- ALVR ASH20--AlloVir Nasdaq: ALVR, a late clinical-stage cell therapy company, today announced that results from the Phase 2, proof-of-concept CHARMS study demonstrated that an allogeneic, off-the-shelf, multi-virus specific T cell therapy, Viralym-M ALVR105, achieved a 93 clinical response and was generally well-tolerated in allogeneic hematopoietic stem cell transplantation allo-HSCT patients with at least one drug refractory infection. The findings were highlight 